Introduction
Traumatic brain injury (TBI) occurs when an external force injures the brain. Motor vehicle accidents cause most TBIs in young adults, while falls are the leading cause of TBIs in people over 65 years of age [
1]. Owing to the increasing use of motor vehicles in developed countries, the incidence of TBI is rapidly growing. TBI is a major cause of death and disabilities—especially in children and young adults—that result in high societal costs [
1,
2]. Men sustain TBIs more frequently than women do. These observations suggest that TBIs result in major health and socioeconomic problems throughout the world. Indeed, the World Health Organization has reported that traffic accidents are the third highest contributor to the global burden of disease and injury [
1,
2].
Neurological damage occurs not only at the moment of impact (primary injury) in a TBI, but also it further develops overtime post-impact. Several processes, such as neurotransmitter release, free-radical generation, calcium-mediated damage, gene activation, mitochondrial dysfunction, and inflammatory responses, have been investigated in studies of the secondary injuries that are associated with TBI [
3‐
5]. These mechanisms might occur continuously over patients’ lifetimes. Interestingly, a history of TBI has been reported to increase the incidence of Alzheimer disease (AD) [
6] and other neurodegenerative conditions, including Parkinson’s disease (PD) [
7], amyotrophic lateral sclerosis (ALS) [
8], and frontotemporal dementia (FTD) [
5]. However, other studies have yielded contradicting results [
9‐
13].
The goal of our study was to determine whether TBI was associated with an increased risk of neurodegeneration by conducting a systematic review of cohort studies of patients with TBI. In addition, we examined which neurodegenerative process occurred most often.
Discussion
Concerns about the relationship between TBI and neurodegeneration have long existed. Our principal finding was that TBI is a potential risk factor for subsequent dementia (1.93, 95% CI = 1.47–2.55), TDP-43 (2.97, 95% CI = 1.35–6.53) and FTD (4.44, 95% CI = 3.86–5.10). However, when we analyzed the associations of the incidences of AD, PD, or dementia with APOE genotype, we found that TBI was not a risk.
A common factor between TBI and different neurodegenerative disorders is the abnormal aggregation, accumulation, and/or disposition of proteins in the brain. Patients with TBI have beta-amyloid deposition in their brains, and the pattern of deposition is similar to that observed in patients with AD. Amyloid precursor protein, β-Amyloid precursor protein-cleaving enzyme-1, and presenilin-1, which is a γ-secretase complex protein, serve as sources of amyloid-β peptide deposition after TBI [
5,
29‐
31].
TBI may also exacerbate nigrostriatal dopaminergic degeneration by modulating PD-associated genes. These results suggest that α-synuclein is a pathological link between the chronic effects of TBI and PD symptoms [
32‐
34].
Another mechanism that might link TBI to neurodegeneration is the accumulation of TDP-43 in patients with FTD and ALS [
5,
24,
37]. Patients with chronic traumatic encephalopathy (CTE) exhibit widespread TDP-43 proteinopathy in multiple areas of the brain [
38]. Some patients also had TDP-43 protein in their spinal cords, and these patients developed a progressive motor neuron disease several years before their deaths [
38,
39]. These findings suggest that TDP-43-associated neurodegeneration and head trauma are connected.
The mechanisms underlying the association of TBI and the incidence of neurodegeneration are exceedingly complex. In fact, in TBI, multiple pathologies occur simultaneously. However, systematic analyses of multiple pathologies in individual cases in a large TBI and control population have not been conducted [
9‐
13,
39]. Therefore, a significant association of AD, PD, and APOE-associated dementia was not observed, and no evidence that head trauma was a risk factor for patients with these disorders was found.
Another noteworthy finding of our study was that AD is not the most common form of neurodegeneration. Several studies have reported that TBI does not affect the development of AD. Whether a single occurrence of moderate-to-severe TBI triggers the development of neurodegeneration remains somewhat controversial [
9‐
13]. In addition, brain injury has been shown to lead to the development of non-AD dementias. However, accurate clinical diagnostic criteria for neurodegeneration that results from TBI do not exist. Therefore, the true risk of neurodegeneration following TBI is hard to define.
Examinations of patients with CTE may help resolve this problem. The symptoms of CTE, which include behavioral disturbances, cognitive dysfunction, and/or motor-related symptoms, generally begin 8–10 years after repetitive mild TBIs are experienced [
40‐
42]. However, the clinical diagnostic criteria for traumatic encephalopathy syndrome have only recently been reported. CTE can be seen after a single moderate or severe TBI while traumatic encephalopathy syndrome exhibits progressive deterioration over time. Therefore, clinical judgment must be used to determine whether the amount of progression is greater than what is expected for the age and comorbidities of the patient [
39‐
42]. Multiple neurodegeneration processes have been used to describe the behavioral disturbances and cognitive dysfunction in patients following TBI owing to the lack of suitable diagnoses. This diagnosis can now be used to define those symptoms.
A major strength of this meta-analysis was the inclusion of a variety of different neurodegenerative outcomes rather than a single diagnosis. The literature search was comprehensive because it focused on diagnoses rather than self-reported symptoms, which resulted in a rigorous examination of the topic.
However, several limitations of this meta-analysis warrant consideration. First, the initial severities of the TBIs varied within and across studies. Since our meta-analyses examined only published data, some important parameters, such as sex, alcohol consumption, and comorbidities were missing. Therefore, we were not able to control for these potential confounding factors. Patients with severe TBI had loss of high cortical function and presented in a vegetative state. In our studies, we included only patients who sought treatment for TBI and neurodegeneration disease, but not important parameters indicating clinical severity and imaging information on TBI. Therefore, it is hard to understand the relationship between the severity of TBI and neurodegeneration disease.
Second, we were not able to examine the effects of the locations of the TBIs in this analysis. Some investigators have proposed that temporal and frontal lobe lesions are more likely to be associated with an increased risk of later dementia compared with lesions in other brain regions [
5]. In addition, preinjury intelligence and education level are also associated with TBI and dementia. However, the effects of these factors in this study were difficult to determine.
Another limitation was that none of the studies included in this review provided information on genetics [
8]. The estimated effect of the apolipoprotein E (
APOE) gene 4 on functional outcome might be greatly confounded by such factors, which could thus influence the validity of any meta-analysis that uses unadjusted results. Therefore, future studies on the relationship between
APOE 4 expression and the functional outcome of TBI should consider these important confounding factors. The age may also have an effect on the patients with neurodegeneration diseases. The risk between early-onset and late-onset neurodegeneration diseases maybe different. The patient with young onset neurodegeneration diseases more likely has a genetic or metabolic disease. However, neurodegeneration diseases are far more common in geriatric population, and researches in neurodegeneration disease are focused mainly on old persons. Therefore, it is hard to understand the association between age and neurodegeneration diseases in our study.
Conclusion
Patients with TBI frequently exhibit neurodegeneration. The symptoms of these neurodegenerative processes include behavioral disturbances, cognitive dysfunction, and/or motor-related symptoms. TBI is a potential risk factor only for subsequent dementia, TDP-43, and FTD, but not for AD, PD, or APOE-associated neurodegeneration. The epidemiology and pathology of this association have been difficult to establish. No suitable criteria define these neurodegenerative processes. However, the diagnosis of CTE may help to resolve this problem. Although the evidence suggested that TBI was a risk factor for neurodegeneration, there is limited information on the type, frequency, or amount of trauma that was necessary to induce the neurodegenerative processes. Therefore, further studies in this area are necessary to answer these questions and determine whether the proper management of TBI is effective in reducing the incidence of neurodegeneration.